Covered recipient · General Payments record
MAUREEN MOOMJY
Allopathic & Osteopathic Physicians Obstetrics & Gynecology Reproductive Endocrinology
General Payments · PY2018–2024
$2,591.78
- Reported across 110 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $279.19 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Ferring Pharmaceuticals Inc. | $75.11 | 4 |
| Astellas Pharma US Inc | $54.76 | 3 |
| ABBVIE INC. | $44.97 | 2 |
| Exeltis, USA Inc. | $35.44 | 2 |
| Almatica Pharma Inc. | $18.56 | 1 |
| Lilly USA, LLC | $18.39 | 1 |
| PFIZER INC. | $17.60 | 1 |
| Novo Nordisk AS | $14.36 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.95 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105058592 | CMS |
| ABBVIE INC. | $24.02 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105058594 | CMS |
| Almatica Pharma LLC | $18.56 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137572164 | CMS |
| Astellas Pharma US Inc | $15.72 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139324838 | CMS |
| Astellas Pharma US Inc | $15.32 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139392812 | CMS |
| Astellas Pharma US Inc | $23.72 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139400433 | CMS |
| Exeltis, USA Inc. | $18.89 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149999854 | CMS |
| Exeltis, USA Inc. | $16.55 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1149999856 | CMS |
| Ferring Pharmaceuticals Inc. | $18.23 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137496698 | CMS |
| Ferring Pharmaceuticals Inc. | $22.24 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137496702 | CMS |
| Ferring Pharmaceuticals Inc. | $19.98 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137496706 | CMS |
| Ferring Pharmaceuticals Inc. | $14.66 | 12/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137496711 | CMS |
| Lilly USA, LLC | $18.39 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135196618 | CMS |
| Novo Nordisk Inc | $14.36 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097457996 | CMS |
| PFIZER INC. | $17.60 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131487170 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.